Video course abdominal ultrasound
Examination of abdominal vessels – Aorta, coeliac trunk and superior mesenteric artery
Author: Prof. Dr. Christoph F. Dietrich ©2019 Falk Foundation e.V., Freiburg. All rights reserved.
Please switch on your loudspeakers!Link to Falk Mediacenter
Latest research in brief:Bowel
Holvoet T et al, Gastroenterology. 2021;160(1):145–57.e8
Fecal microbiota transfer (FMT) for patients with irritable bowel syndrome (IBS): In a randomized trial of patients with refractory IBS with predominant bloating, FMT relieved symptoms compared to placebo (transfer of autologous stool). The effects decreased after 1 year and could be restored by a second FMT in patients with prior response. Clinical response was also associated with composition of the fecal microbiota which may serve as biomarker for future response to therapy.
Sævik F et al, J Crohns Colitis. 2021;15(1):115–24
Ultrasound for monitoring disease activity of Crohn’s disease:): A simple ultrasound activity index consisting of bowel thickness and color Doppler was constructed and validated and correlated well with endoscopic disease activity.
Beyna T et al, Gut. 2021;70(2):261–7
Motorized spiral endoscopy: This first prospective clinical feasibility study comprising 140 interventions demonstrated that motorized spiral endoscopy has a high diagnostic yield of 74,2% with an acceptable spectrum of side effects.
Galaski J et al, J Hepatol. 2021;74(2):312–20
NoAutoimmune hepatitis (AIH):The simplified criteria for the diagnosis of AIH include immunofluorescence testing of antinuclear and smooth muscle autoantibodies (ANA and SMA) on rodent tissue sections. A current study demonstrates that at adjusted cut-offs, both ANA immunofluorescence testing using human epithelioma-2 cells and ELISA-based autoantibody evaluation for ANA and SMA are potential alternatives.
de Vries E et al, Gastroenterology. 2021;160(3):734–43.e6
AcuPrimary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC): A recent double-blind, randomized, placebo-controlled trial indicates that bezafibrat (400 mg/day) may substantially improve moderate-to-severe pruritus in these conditions.
Mahmud N et al, Hepatology. 2021;73(1):204–18
Postoperative mortality in cirrhosis: A new online tool substantially improves postoperative mortality predictions in patients with cirrhosis. Predictors include age, preoperative albumin, platelet count, bilirubin, surgery category, emergency indication, fatty liver disease, ASA (American Society of Anesthesiologists) classification, and obesity. (www.vocalpennscore.com
O’Hara J et al, BMJ. 2021;372:m4903
Proton-pump inhibitors (PPI) to treat persistent throat symptoms: There was no benefit from PPI therapy in patients with persistent throat symptoms in a randomized placebo-controlled trial.
Chiang TH et al, Gut. 2021;70(2):243–50
Helicobacter pylori eradication for prevention of gastric cancer: Population-based eradication of H. pylori significantly reduced gastric cancer incidence in a high-risk cohort in Taiwan without causing significant side effects. However, there was no impact on tumor-associated mortality, but the follow-up may not have been sufficiently long to address this question.
Rinott E et al, Gastroenterology. 2021;160(1):158–73.e10
Effects of diet-modulated autologous fecal microbiota transfer (FMT) on weight regain: FMT of autologous stool collected during the weight-loss phase and administered during the weight gain phase preserved weight loss and glycemic control and was associated with specific microbiome signatures. This approach was particularly successful using a high-polyphenol, green plant-based or Mankai diet.
Boxhoorn L et al, Endoscopy. 2021;53(2):136–44
Outcomes of endoscopic treatment for symptomatic sterile walled-off necrosis: Results of a multicenter retrospective cohort study suggest that endoscopic transluminal drainage results in clinical success in the long term. However, the majority of patients required additional re-interventions for clinically relevant iatrogenic infections.
Online Live Event
Gut Microbiome: Structure, Metabolic Activity and Clinical Application
Originally the event was planned to take place in Sydney, however, due to the ongoing Covid-19 pandemic, this has transformed to our online event with the face to face symposium to follow in 2022.
Being fully aware of the different time zones of participants, the Online Event will be run in two sessions; the same topics will be covered in both sessions but our expert speakers, who will form part of the live discussion panel, have been chosen based on location/time zone.
March 3 – 4, 2021
Session I (mainly timed for Australia, Asia and Europe):
March 3, 07.00 – 09.45 h UTC
Session II (mainly timed for Australia and USA):
March 3, 22.00 – March 4, 00.45 h UTC
Current Falk literature: